Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Current Investments (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Cash & Current Investments data on record, last reported at $87.6 million in Q1 2024.

  • For Q1 2024, Cash & Current Investments rose 2.73% year-over-year to $87.6 million; the TTM value through Mar 2024 reached $87.6 million, up 2.73%, while the annual FY2025 figure was $678.0 million, 671.38% up from the prior year.
  • Cash & Current Investments reached $87.6 million in Q1 2024 per RDY's latest filing, up from $85.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $474.2 million in Q1 2021 and bottomed at $43.6 million in Q1 2020.
  • Average Cash & Current Investments over 5 years is $182.7 million, with a median of $87.6 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: plummeted 87.58% in 2020, then surged 987.74% in 2021.
  • A 5-year view of Cash & Current Investments shows it stood at $43.6 million in 2020, then soared by 987.74% to $474.2 million in 2021, then crashed by 53.0% to $222.9 million in 2022, then plummeted by 61.73% to $85.3 million in 2023, then grew by 2.73% to $87.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $87.6 million in Q1 2024, $85.3 million in Q1 2023, and $222.9 million in Q1 2022.